Histopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejection

Xenotransplantation

Volumn 20, Issue 5, 2013, Pages 292-307

  Byrne, Guerard W ^a,b   Azimzadeh, Agnes M ^c   Ezzelarab, Mohamed ^d   Tazelaar, Henry D ^e   Ekser, Burcin ^d   Pierson, Richard N ^c   Robson, Simon C ^f   Cooper, David K C ^d   McGregor, Christopher G A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

cardiac transplantation; coagulation; complement activation; Gal epitope; orthotopic transplantation; xenotransplantation

Indexed keywords

ANTI NON GAL ANTIBODY; ANTIBODY; COMPLEMENT; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY MEDIATED REJECTION; APOPTOSIS; CARDIAC GRAFT REJECTION; COMPLEMENT DEPOSITION; DRUG MECHANISM; GRAFT SURVIVAL; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; XENOGRAFT; XENOTRANSPLANTATION; ANIMAL; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOLOGY; PROCEDURES; SWINE;

ANIMALS; ANTIBODIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HETEROGRAFTS; HUMANS; IMMUNOSUPPRESSION; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84885142072     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12050     Document Type: Review

References (132)

1. McGregor CG, Davies WR, Oi K, et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851.
2. Mohiuddin MM, Corcoran PC, Singh AK, et al. B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8 months. Am J Transplant 2012; 12: 763-771.
3. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31.
4. Good AH, Cooper DKC, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992; 24: 559-562.
5. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC,. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391-11395.
6. Oriol R, Ye Y, Koren E, Cooper DKC,. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation 1993; 56: 1433-1442.
7. Cooper DKC, Good AH, Koren E, et al. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1993; 1: 198-205.
8. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423-427.
9. Cozzi E, White DJG,. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964-966.
10. Fischel RJ, Matas AJ, Perry E, et al. Plasma exchange, organ perfusion, and immunosuppression reduce "natural" antibody levels as measured by binding to xenogeneic endothelial cells and prolong discordant xenograft survival. Transplant Proc 1992; 24: 574-575.
11. Taniguchi S, Neethling FA, Korchagina EY, et al. In vivo immunoadsorption of antipig antibodies in baboons using a specific Gal(alpha)1-3Gal column. Transplantation 1996; 62: 1379-1384.
12. Xu Y, Lorf T, Sablinski T, et al. Removal of anti-porcine natural antibodies from human and nonhuman primate plasma in vitro and in vivo by a Gal(alpha)1-3Gal(beta)1-4(beta)Glc-X immunoaffinity column. Transplantation 1998; 65: 172-179.
13. Kozlowski T, Ierino FL, Lambrigts D, et al. Depletion of anti-Gal(alpha)1-3Gal antibody in baboons by specific a-Gal immunoaffinity columns. Xenotransplantation 1998; 5: 122-131.
14. Watts A, Foley A, Awwad M, et al. Plasma perfusion by apheresis through a Gal immunoaffinity column successfully depletes anti-Gal antibody: experience with 320 aphereses in baboons. Xenotransplantation 2000; 7: 181-185.
15. Ye Y, Neethling FA, Niekrasz M, et al. Evidence that intravenously administered a-Galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15) and transplanted pig hearts. Transplantation 1994; 58: 330-337.
16. Nagasaka T, Kobayashi T, Muramatsu H, et al. alpha Galactosyl oligosaccharides conjugated with polyethylene glycol as potential inhibitors of hyperacute rejection upon xenotransplantation. Biochem Biophys Res Commun 1997; 232: 731-736.
17. Rieben R, Bovin NV, Korchagina EY, et al. Xenotransplantation: in vitro analysis of synthetic a-galactosyl inhibitors of human anti-Gal(alpha)1-3Gal IgM and IgG antibodies. Glycobiology 2000; 10: 141-148.
18. Byrne GW, Schwarz A, Fesi JR, et al. Evaluation of different alpha-Galactosyl glycoconjugates for use in xenotransplantation. Bioconjug Chem 2002; 13: 571-581.
19. Diamond LE, Byrne GW, Schwarz A, et al. Analysis of the control of the anti-Gal immune response in a non-human primate by galactose alpha-1-3 galactose trisaccharide-polyethylene glycol conjugate. Transplantation 2002; 73: 1780-1787.
20. Lai L, Kolber-Simonds D, Park K-W, et al. Production of a-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295: 1089-1092.
21. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
22. Sharma A, Naziruddin B, Cui C, et al. Pig cells that lack the gene for alpha1-3 galactosyltransferase express low levels of the gal antigen. Transplantation 2003; 75: 430-436.
23. Lexer G, Cooper DK, Rose AG, et al. Hyperacute rejection in a discordant (pig to baboon) cardiac xenograft model. J Heart Transplant 1986; 5: 411-418.
24. Cooper DKC, Human PA, Lexer G, et al. Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J Heart Transplant 1988; 7: 238-246.
25. Rose AG, Path M, Cooper DKC, et al. Histopathology of hyperacute rejection of the heart: experimental and clinical observations in allografts and xenografts. J Heart Lung Transplant 1991; 10: 223-234.
26. Platt JL, Fischel RJ, Matas AJ, et al. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214-220.
27. Wu G, Pfeiffer S, Schroder C, et al. Co-stimulation blockade targeting CD154 and CD28/B7 modulates the induced antibody response after a pig-to-baboon cardiac xenograft. Xenotransplantation 2005; 12: 197-208.
28. Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745-1756.
29. Lin SS, Hanaway MJ, Gonzalez-Stawinski GV, et al. The role of anti-Gal-alpha-1-3Gal antibodies in acute vascular rejection and accommodation of xenografts. Transplantation 2000; 70: 1667-1674.
30. Kozlowski T, Shimizu A, Lambrigts D, et al. Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption. Transplantation 1999; 67: 18-30.
31. Kuwaki K, Knosalla C, Dor FJMF, et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4: 363-372.
32. Lam TT, Paniagua R, Shivaram G, et al. Anti-non-Gal porcine endothelial cell antibodies in acute humoral xenograft rejection of hDAF-transgenic porcine hearts in cynomolgus monkeys. Xenotransplantation 2004; 11: 531-535.
33. McGregor CGA, Teotia SS, Byrne GW, et al. Cardiac xenotransplantation: progress toward the clinic. Transplantation 2004; 78: 1569-1575.
34. Wu G, Pfeiffer S, Schroder C, et al. Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes. Xenotransplantation 2007; 14: 34-47.
35. Houser SL, Kuwaki K, Knosalla C, et al. Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11: 416-425.
36. Byrne GW, Davies WR, Oi K, et al. Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival. Transplantation 2006; 82: 1787-1791.
37. Byrne GW, Schirmer JM, Fass DN, et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005; 5: 1011-1020.
38. Tazelaar HD, Byrne GW, McGregor CG,. Comparison of Gal and non-Gal-mediated cardiac xenograft rejection. Transplantation 2011; 91: 968-975.
39. Shimizu A, Hisashi Y, Kuwaki K, et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008; 172: 1471-1481.
40. Ierino FL, Kozlowski T, Siegel JB, et al. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts. Transplantation 1998; 66: 1439-1450.
41. Ezzelarab M, Garcia B, Azimzadeh A, et al. The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation 2009; 87: 805-812.
42. Lin CC, Ezzelarab M, Shapiro R, et al. Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant 2010; 10: 1556-1568.
43. Mazzucato M, Demarco L, Pradella P, Masotti A, Pareti FI,. Porcine von Willebrand factor binding to human platelet GPIb induces transmembrane calcium influx. Thromb Haemost 1996; 75: 655-660.
44. Kopp CW, Grey ST, Siegel JB, et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells. Transplantation 1998; 66: 244-251.
45. Siegel JB, Grey ST, Lesnikoski BA, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64: 888-896.
46. Lawson JH, Daniels LJ, Platt JL,. The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc 1997; 29: 884-885.
47. Rood PP, Hara H, Busch JL, et al. Incidence and cytotoxicity of antibodies in cynomolgus monkeys directed to nonGal antigens, and their relevance for experimental models. Transpl Int 2006; 19: 158-165.
48. Byrne GW, Stalboerger PG, Davila E, et al. Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation 2008; 15: 268-276.
49. McGregor CG, Ricci D, Miyagi N, et al. Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts. Transplantation 2012; 93: 686-692.
50. Lin CC, Chen D, McVey JH, Cooper DK, Dorling A,. Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells. Transplantation 2008; 86: 702-709.
51. Lin CC, Ezzelarab M, Hara H, et al. Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells. J Thromb Haemost 2010; 8: 2001-2010.
52. Simioni P, Boldrin M, Gavasso S, et al. Effects of long-term administration of recombinant human protein C in xenografted primates. Transplantation 2011; 91: 161-168.
53. Cozzi E, Simioni P, Boldrin M, et al. Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 2005; 80: 1501-1510.
54. Schirmer JM, Fass DN, Byrne GW, et al. Effective antiplatelet therapy does not prolong transgenic pig to baboon cardiac xenograft survival. Xenotransplantation 2004; 11: 436-443.
55. Buhler L, Basker M, Alwayn IPJ, et al. Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000; 70: 1323-1331.
56. Cowan PJ, Aminian A, Barlow H, et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69: 2504-2515.
57. Manez R, Lopez-Pelaez E, Centeno A, et al. Transgenic expression in pig hearts of both human decay-accelerating factor and human membrane cofactor protein does not provide an additional benefit to that of human decay-accelerating factor alone in pig-to-baboon xenotransplantation. Transplantation 2004; 78: 930-933.
58. Schmoeckel M, Bhatti FNK, Zaidi A, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998; 65: 1570-1577.
59. Vogel CW, Fritzinger DC, Hew BE, Thorne M, Bammert H,. Recombinant cobra venom factor. Mol Immunol 2004; 41: 191-199.
60. Kourtzelis I, Markiewski MM, Doumas M, et al. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 2010; 116: 631-639.
61. Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185: 5628-5636.
62. Laudes IJ, Chu JC, Sikranth S, et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002; 160: 1867-1875.
63. Huber-Lang MS, Sarma JV, McGuire SR, et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 2001; 15: 568-570.
64. Guo RF, Ward PA,. Role of C5a in inflammatory responses. Annu Rev Immunol 2005; 23: 821-852.
65. Ikeda K, Nagasawa K, Horiuchi T, et al. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77: 394-398.
66. Cowan PJ, Robson SC, D'apice AJ,. Controlling coagulation dysregulation in xenotransplantation. Curr Opin Organ Transplant 2011; 16: 214-221.
67. Altieri DC, Capitanio AM, Mannucci PM,. von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol 1986; 63: 703-711.
68. Roussel JC, Moran CJ, Salvaris EJ, et al. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8: 1101-1112.
69. Xu H, Arnaud F, Tadaki DK, et al. Human platelets activate porcine endothelial cells through a CD154-dependent pathway. Transplantation 2001; 72: 1858-1861.
70. Al-Mohanna F, Collison K, Parhar R, et al. Activation of naive xenogeneic but not allogeneic endothelial cells by human naive neutrophils: a potential occult barrier to xenotransplantation. Am J Pathol 1997; 151: 111-120.
71. Goodman DJ, von Albertini M, Willson A, Millan MT, Bach FH,. Direct activation of porcine endothelial cells by human natural killer cells. Transplantation 1996; 61: 763-771.
72. Sheikh S, Parhar R, Al-Mohanna F,. Rapid static adhesion of human naive neutrophil to naive xenoendothelium under physiologic flow is independent of Galalpha1,3-gal structures. J Leukoc Biol 2002; 71: 932-940.
73. Al-Mohanna F, Saleh S, Parhar RS, Khabar K, Collison K,. Human neutrophil gene expression profiling following xenogeneic encounter with porcine aortic endothelial cells: the occult role of neutrophils in xenograft rejection revealed. J Leukoc Biol 2005; 78: 51-61.
74. Schneider MK, Seebach JD,. Current cellular innate immune hurdles in pig-to-primate xenotransplantation. Curr Opin Organ Transplant 2008; 13: 171-177.
75. Buhler L, Awwad M, Basker M, et al. High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 2000; 69: 2296-2304.
76. Knosalla C, Gollackner B, Cooper DKC,. Anti-CD154 monoclonal antibody and thromboembolism revisited. Transplantation 2002; 74: 416-417.
77. Knosalla C, Ryan DJ, Moran K, et al. Initial experience with the human anti-human CD154 monoclonal antibody, ABI793, in pig-to-baboon xenotransplantation. Xenotransplantation 2004; 11: 353-360.
78. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB,. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
79. Charafeddine AH, Kim EJ, Maynard DM, et al. Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation. Am J Transplant 2012; 12: 3143-3151.
80. Waterworth PD, Dunning J, Tolan M, et al. Life-supporting pig-to-baboon heart xenotransplantation. J Heart Lung Transplant 1998; 17: 1201-1207.
81. Vial CM, Ostlie DJ, Bhatti FNK, et al. Life supporting function for over one month of a transgenic porcine heart in a baboon. J Heart Lung Transplant 2000; 19: 224-229.
82. Xu H, Gundry SR, Hancock WW, et al. Prolonged discordant xenograft survival and delayed xenograft rejection in a pig-to-baboon orthotopic cardiac xenograft model. J Thorac Cardiovasc Surg 1998; 115: 1342-1349.
83. McGregor CGA, Davies WR, Oi K, et al. Recovery of cardiac function after pig-to-primate orthotopic heart transplant. (Abstr 98). Am J Transplant 2008; 8: 205-206.
84. Brandl U, Michel S, Erhardt M, et al. Transgenic animals in experimental xenotransplantation models: orthotopic heart transplantation in the pig-to-baboon model. Transplant Proc 2007; 39: 577-578.
85. Brandl U, Michel S, Erhardt M, et al. Administration of GAS914 in an orthotopic pig-to-baboon heart transplantation model. Xenotransplantation 2005; 12: 134-141.
86. McGregor CGA, Byrne GW, Vlasin M, et al. Cardiac function after preclinical orthotopic cardiac xenotransplantation. Am J Transplant 2009; 9: 380.
87. Byrne GW, McGregor CG,. Cardiac xenotransplantation: progress and challenges. Curr Opin Organ Transplant 2012; 17: 148-154.
88. Azimzadeh A, Kelishadi S, Ezzelarab M, et al. Early graft failure of GTKO pigs organs in baboons is reduced by hCPRP expression. Xenotransplantation 2009; 16: 356.
89. Miwa Y, Yamamoto K, Onishi A, et al. Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation. Xenotransplantation 2010; 17: 26-37.
90. Yazaki S, Iwamoto M, Onishi A, et al. Production of cloned pigs expressing human thrombomodulin in endothelial cells. Xenotransplantation 2012; 19: 82-91.
91. Ekser B, Ezzelarab M, Hara H, et al. Clinical xenotransplantation: the next medical revolution? Lancet 2012; 379: 672-683.
92. Cooper DK, Ekser B, Burlak C, et al. Clinical lung xenotransplantation- what donor genetic modifications may be necessary? Xenotransplantation 2012; 19: 144-158.
93. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243.
94. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
95. Cooper DKC, Keogh AM, Brink J, et al. Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant 2000; 19: 1125-1165.
96. Schuurman H-J, Pino-Chavez G, Phillips MJ, et al. Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors. Transplantation 2002; 73: 1146-1151.
97. Schuurman H-J, Cheng J, Lam T,. Pathology of xenograft rejection: a commentary. Xenotransplantation 2003; 10: 293-299.
98. Byrne GW, Du Z, Sun Z, Asmann YW, McGregor CG,. Changes in cardiac gene expression after pig-to-primate orthotopic xenotransplantation. Xenotransplantation 2011; 18: 14-27.
99. Knosalla C, Yazawa K, Behdad A, et al. Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation. Am J Transplant 2009; 9: 1006-1016.
100. Ryan JB, Hicks M, Cropper JR, et al. Cariporide (HOE-642) improves cardiac allograft preservation in a porcine model of orthotopic heart transplantation. Transplantation 2003; 75: 625-631.
101. Hing AJ, Watson A, Hicks M, et al. Combining cariporide with glyceryl trinitrate optimizes cardiac preservation during porcine heart transplantation. Am J Transplant 2009; 9: 2048-2056.
102. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-1561.
103. Costa C, Bell NK, Stabel TJ, Fodor WL,. Use of porcine tumor necrosis factor receptor 1-Ig fusion protein to prolong xenograft survival. Xenotransplantation 2004; 11: 491-502.
104. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
105. Batten P, Yacoub MH, Rose ML,. Effect of human cytokines (IFN-y, TNF-a, IL-1b, IL-4) on porcine endothelial cells: induction of MHC and adhesion molecules and functional significance of these changes. Immunology 1996; 87: 127-133.
106. Wheeler DG, Joseph ME, Mahamud SD, et al. Transgenic swine: expression of human CD39 protects against myocardial injury. J Mol Cell Cardiol 2012; 52: 958-961.
107. Byrne GW, Stalboerger PG, Du Z, Davis TR, McGregor CG,. Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation 2011; 91: 287-292.
108. Diswall M, Angstrom J, Karlsson H, et al. Structural characterization of alpha1,3-galactosyltransferase knockout pig heart and kidney glycolipids and their reactivity with human and baboon antibodies. Xenotransplantation 2010; 17: 48-60.
109. Burlak C, Wang ZY, Chihara RK, et al. Identification of human preformed antibody targets in GTKO pigs. Xenotransplantation 2012; 19: 92-101.
110. Padler-Karavani V, Varki A,. Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation 2011; 18: 1-5.
111. Miwa Y, Kobayashi T, Nagasaka T, et al. Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation? Xenotransplantation 2004; 11: 247-253.
112. Zhu A, Hurst R,. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002; 9: 376-381.
113. Bouhours D, Pourcel C, Bouhours J-F,. Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Gal(alpha)1-3Gal), blood group H determinant and N-glycolylneuraminic acid. Glycoconj J 1996; 13: 947-953.
114. Saethre M, Baumann BC, Fung M, Seebach JD, Mollnes TE,. Characterization of natural human anti-non-gal antibodies and their effect on activation of porcine gal-deficient endothelial cells. Transplantation 2007; 84: 244-250.
115. Blixt O, Kumagai-Braesch M, Tibell A, Groth CG, Holgersson J,. Anticarbohydrate antibody repertoires in patients transplanted with fetal pig islets revealed by glycan arrays. Am J Transplant 2009; 9: 83-90.
116. Padler-Karavani V, Yu H, Cao H, et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008; 18: 818-830.
117. Bovin N, Obukhova P, Shilova N, et al. Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies? Biochim Biophys Acta 2012; 1820: 1373-1382.
118. Pochechueva T, Jacob F, Goldstein DR, et al. Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies. Glycoconj J 2011; 28: 507-517.
119. Lutz AJ, Li P, Estrada JL, et al. Double knockout pigs deficient in N-glycolylneuraminic acid and Galactose alpha-1,3-Galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation 2013; 20: 27-35.
120. Yeh P, Ezzelarab M, Bovin N, et al. Investigation of potential carbohydrate antigen targets for human and baboon antibodies. Xenotransplantation 2010; 17: 197-206.
121. Ezzelarab M, Hara H, Busch J, et al. Antibodies directed to pig non-Gal antigens in naive and sensitized baboons. Xenotransplantation 2006; 13: 400-407.
122. Buhler L, Xu Y, Li W, Zhu A, Cooper DK,. An investigation of the specificity of induced anti-pig antibodies in baboons. Xenotransplantation 2003; 10: 88-93.
123. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-755.
124. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006; 91: 586-599.
125. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-2114.
126. Petersen B, Ramackers W, Tiede A, et al. Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation 2009; 16: 486-495.
127. Klymiuk N, Wuensch A, Kurome M, et al. GalT-KO/CD46/hTM triple-transgenic donor animals for pig-to-baboon heart transplantation. Xenotransplantation 2011; 18: 271.
128. Iwamoto M, Yazaki S, Onishi A, et al. Successful production and breeding of cloned pigs expressing human thrombomodulin in endothelial cells. Xenotransplantation 2011; 18: 270.
129. Salvaris E, Fisicaro N, Harrison S, et al. Expression of human thrombomodulin in GTKO/hCD55-hCD59-HTF pigs. Xenotransplantation 2011; 18: 296.
130. Ezzelarab C, Ayares D, Cooper DK, Ezzelarab MB,. Human T-cell proliferation in response to thrombin-activated GTKO pig endothelial cells. Xenotransplantation 2012; 19: 311-316.
131. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113: 1440-1446.
132. Crikis S, Lu B, Murray-Segal LM, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010; 10: 2586-2595.